FDA Grants Priority Review to Zongertinib for HER2-Mutated NSCLC
Stephen Liu, MD, Shares Insights on the eNRGy Trial
CheckMate-816 Shows Significant Improvement in OS With Neoadjuvant Nivolumab Plus Chemotherapy for Resectable NSCLC